Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients Autologous peripheral blood stem cell transplant continues to be one of the standard treatment options for patients with myeloma younger than 70 years of age following induction therapy. Risk factors for impaired stem cell collection include previous exposure to alkylating agents (that is, melphalan), radiation and extensive bone marrow plasma cell infiltration. 1 The mobilization strategy employed may also affect stem cell yield. 2 Immunomodulatory drugs (for example, thalidomide and lenalidomide) are increasingly being used for induction therapy in patients with multiple myeloma. The impact of these novel agents on stem cell mobilization is worth noting. We have previously reported that induction therapy with a thalidomidebased regimen leads to a lower yield of stem cells when compared to bortezomib. 3 Thalidomide use was associated with a reduced yield of stem cells per collection and an increased number of phereses were required to reach pre-determined target goals. Delay in engraftment of platelets by a median of 1 day was also observed.
We read with interest the article by Kumar et al., 4 who reported their experience with mobilizing peripheral blood stem cells (PBSCs) after induction therapy with lenalidomide and dexamethasone. In patients mobilized with granulocyte-colony stimulation factor (G-CSF) alone after treatment with lenalido- Letters to the Editor mide, they observed a significant decrease in total CD34 þ cells per kg, average daily yield, day 1 yield and an increased number of phereses were required compared to historical controls treated with dexamethasone alone, thalidomide-dexamethasone or vincristine, adriamycin and dexamethasone chemotherapy. The decrease in PBSC yield correlated with the length of lenalidomide therapy. Regardless, neutrophil and platelet engraftments post-transplant were similar. They recommended PBSC collection be completed within 6 months of initiation of lenalidomide therapy to minimize this decreased yield. We confirm the observation of lower PBSC yield after lenalidomide induction therapy. Data were pooled from three centers from patients who had received lenalidomide induction therapy followed by PBSC mobilization. All patients received G-CSF 10 mg kg À1 for 4 days, except for patients 1-8 who were mobilized with 7.5 mcg kg À1 G-CSF and 7.5 mg kg À1 GM-CSF for 5 days as indicated in Table 1 .
Twelve of 28 patients (43%) failed to collect sufficient cells for even one transplant (o2 Â 10 6 CD34 þ cells per kg). It should be noted that three patients also failed to mobilize sufficient stem cells when treated with the CXCR4 inhibitor AMD3100 plus G-CSF on a compassionate use protocol. These patients subsequently had successful mobilization following cyclophosphamide chemotherapy. Similar to the Mayo Clinic observations, for patients who did mobilize X2 Â 10 6 CD34 þ cells per kg, engraftment kinetics were comparable to patients treated with other induction regimens.
Our data mirrored those of Kumar et al. 4 in several aspects. After lenalidomide therapy, there was a decrease in the total number of CD34 þ cells per kg, day 1 collection and the total number of days required to collect sufficient CD34 þ cells compared to chemotherapy and/or bortezomib induction therapy 3 (data not shown). Our data differed from those of Kumar et al. 4 regarding the correlation of the number of cycles of lenalidomide therapy and subsequent PBSC mobilization. They reported no mobilization failures in patients who had less than six cycles of lenalidomide. In contrast, 6 of 12 of our failures had received five or less cycles of lenalidomide. Furthermore, unlike their observations, the length of time of lenalidomide therapy did not clearly correlate with the number of CD34 þ cells obtained. Thus, the optimal time to mobilize CD34 þ cells is not clear. On the basis of these data, we recommend cyclophosphamide for mobilization of patients with prior lenalidomide exposure. We would like to commend Professor Mazumder et al. 1 for presenting additional data that confirm our initial observation of decreased stem mobilization following the use of lenalidomidebased therapies for newly diagnosed myeloma. 2 The rate of peripheral blood stem cell collection failure in this report is higher than what we have observed in our analysis of all patients with myeloma undergoing an attempt at stem collection. To some extent, this probably reflects the total number of apheresis that the patients were subjected to. The median number of collections from patients who had prior lenalidomide was five in our study compared to three in the current report. Also, it is not clear whether every patient who received lenalidomide-based initial therapy, who came to stem collection at the three institutions, were included in the study. Irrespective of the differences in the two studies, both convey the same message.
Physicians and patients should be aware of the potential for mobilization failures when lenalidomide is used for initial therapy. Whether this is a function of one or more of the factors such as older age, longer duration of therapy or interval from the last dose of lenalidomide to initiation of growth factors needs to be further studied in this patient group. Clearly, use of chemotherapy for mobilization is an option in these patients. It is unclear whether we need to adopt this for all the patients, or only use this for rescue in case of initial failure. A longer rest period off lenalidomide (approximately 4 weeks) prior to stem cell mobilization may be helpful, and we have initiated this change at our institution. We believe that once mobilizing agents such as AMD-3100 become available, this issue will be resolved to a large extent.
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